OSCR · Oscar Health, Inc.

The thesis

Oscar Health's 2026 profit guidance was raised in September, but the shares have slipped to $31.10 from a $34.32 52-week high ahead of the 5 November 2026 third-quarter report, which decides whether the raised range holds. The evidence supports the guidance for 2026. It does not yet show the shares beating the S&P 500 over the next three months, because 2027 enrollment in a shrinking subsidised market is unresolved.

The adjusted daily close on 26 October 2026 was $31.10, 9.4% below the 52-week high of $34.32. The close was $33.79 on 13 October and $30.84 on 30 September. The 14-day relative strength index (RSI) is 43.4, and the three-month price change is 1.7%.

The narrative is maturing: the profitability story has been widely known since the 16 September Investor Day, and the news since 14 October concerns 2027 expansion, not new earnings. On 21 October 2026, Health Care Dive reported that Oscar is adding 140 counties for 2027, including its first entry into South Carolina.

Bullish and bearish views on Oscar Health, Inc.

The bull case on Oscar Health, Inc. (OSCR), in brief: Management raised the profit guide. The bear case: Several targets sit near or below the price.

Bull case

• Management raised the profit guide. Oscar's 16 September 2026 Form 8-K raised 2026 earnings from operations (EFO) to $600–800 million from $500–700 million. Revenue stayed at $18.7–19.0 billion, and the medical loss ratio (MLR, medical costs as a share of premiums) is guided to 81.0–82.0%.
• Reported earnings have already swung. The 6 August 2026 release reported second-quarter net income attributable to Oscar of $361.8 million, against a $228.4 million loss a year earlier.
• The footprint is growing while rivals trim. Health Care Dive (21 October 2026) reports Oscar adding 140 counties for 2027 and planning 400 to 600 new counties by 2029. Centene's net footprint change is zero, and UnitedHealthcare is leaving Georgia.
• Several analysts sit well above the price. Barclays (Overweight) has a $49 target and Raymond James (Outperform) $42, both set 17 September–18. UBS kept Neutral and raised its target to $36 on 12 October.

Bear case

• Several targets sit near or below the price. BofA Securities kept Underperform with a $30 target and Baird kept Neutral at $33 on 17 September 2026. Stephens holds Equal-Weight at $34.
• The subsidised pool is shrinking. KFF data cited by Health Care Dive (21 October 2026) shows ACA enrollment down by more than 4.6 million as of June. A White House task force and the Centers for Medicare & Medicaid Services (CMS) announced on 22 September–23 the cancellation of subsidy payments for about 760,000 enrollments, an estimated $2.2 billion.
• 2027 pricing tests demand. Remaining insurers propose a median 15% rate increase for 2027, the highest back-to-back rise since 2018, per the Commonwealth Fund as cited by Health Care Dive. The same report describes a smaller, apparently sicker risk pool expected to raise insurer spending.
• Second-quarter profit leaned on reserves. The 6 August release cited $164 million of favorable prior-period reserve development. The third and fourth quarters carry the seasonally higher loss ratio.

Price setup

The adjusted close on 26 October 2026 was $31.10. The 52-week high of $34.32 was set after the $34.01 close of 12 October. The $29.60 weekly close of 25 September, after Thrive-affiliated funds distributed about 6.3 million Class A shares in kind, is the lowest recent reference point. RSI of 43.4 shows momentum has faded from the 68.0 reading of 13 October.

Crowding evidence is mixed. The earnings date is nine days away. Benzinga flagged large options trades in Oscar on 10 September, 11 and 16, around the guidance raise. No SEC Form 4 insider sales or new filings appear in the last 30 days.

The pullback after the guidance rally leaves the stock between the 30 September close of $30.84 and the October highs. A close below $30.84 on a weekly basis would retest the post-distribution low.

Catalysts, next 30 days

• 1 November 2026: HealthCare.gov open enrollment for 2027 begins and runs to 15 January 2027. Early sign-up counts are the first read on whether the pool shrinks further.

Elapsed catalysts

• 5 November 2026: Third-quarter results before the open, 8:00 AM ET call. The report shows whether EFO and MLR track the $600–800 million and 81.0–82.0% ranges, and how much prior-period reserve release contributed. (passed 1d ago)

What would change the view

The case breaks if the 5 November report lowers the EFO floor below $600 million or lifts the MLR ceiling above 82.0%, or if third-quarter results show little favorable prior-period development with a current-year loss ratio above the guided range. Disclosure that Oscar holds a material share of the 760,000 cancelled enrollments, or early 2027 enrollment data showing year-over-year declines in Oscar's main states, would also weaken it. Price-wise, a weekly close below $29.60 would put the shares under the post-distribution low.

Upside evidence would be a third-quarter report that keeps or raises the range with little reserve help, and an enrollment trend that holds Oscar's 2027 membership near the 2.96 million reported at the second quarter.

What it trades with

Oscar moves with other Affordable Care Act exchange insurers, chiefly Centene, on subsidy, rate and enrollment news. Its single-segment ACA book means it has no Medicare Advantage or Medicaid income to offset a weak marketplace quarter. Federal policy headlines on subsidies and enrollment integrity move the shares independently of operating results.